Dietoterapia, nutricion clinica y metabolismo_booksmedicos.org.pdf

128 Dietoterapia, nutrición clínica y metabolismo
26. Van Gaal L, Mertens I, Ballaux D, Verkade HJ. Modern,
new pharmacotherapy for obesity. A gastrointestinal approach.
Best Pract Res Clin Gastroenterol 2004; 18: 1049–
1072.
27. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA,Cortese
C, Bacon BR. Orlistat in the treatment of NASH: A case series.
Am J Gastroenterol 2003; 98: 926-930.
28. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J,
Kalhan S. Effects of moderate weight loss on insulin resistance,
regional adiposity, and fatty acids in type 2 diabetes.
Diabetes Care 2004; 27: 33-40.
29. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL.
Orlistat is as beneficial as metformin in the treatment of
polycystic ovarian syndrome. J Clin Endocrinol Metabol
2005; 90: 729-733.
30. Hsieh CJ, Wang PW, Liu RT, Tung SC, Chien WY, Chen JF, et
al. Orlistat for obesity: benefits beyond weight loss. Diabetes
Res Clin Pract 2005; 67: 78–83.
31. Tiikkainen M, Bergholm R, Rissanen A, Aro A, Salminen I,
Tamminen M, et al. Effects of equal weight loss with orlistat
and placebo on body fat and serum fatty acid composition
and insulin resistance in obese women. Am J Clin Nutr
2004; 79: 22–30.
32. Damci T, Yalin S, Balci Z, et al. Orlistat augments postprandial
increases in glucagon-like peptide 1 in obese type 2
diabetic patients. Diabetes Care 2004; 27: 1077-80.
33. Sari R, Balci MK, Coban E, Yazicioglu G. Comparison of the
effect of orlistat vs orlistat plus metformin on weight loss
and insulin resistance in obese women. Int J Obes 2004; 28:
1059–1063.
34. Curran MP,Scott LJ. Orlistat: a review of its use in the management
of patients with obesity. Drugs 2004; 64: 2845-
2864.
35. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM,
Hubbard VS, et al. Three-month tolerability of orlistat in
adolescents with obesity-related comorbid conditions.
Obes Res 2002; 10: 642– 650.
36. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold
ME, Steinberg CM. Effects of sibutramine plus orlistat in
obese women following 1 year of treatment by sibutramine
alone: a placebo-controlled trial. Obes Res 2000;
8: 431– 437.
37. Kaya A, Aydn N, Topsever P, Filiz M, Öztürk A, Dagar A, et
al. Efficacy of sibutramine, orlistat and combination therapy
on short-term weight management in obese patients.
Biomedicine & Pharmacotherapy 2004; 58: 582–587.
38. Bays HE. Antiobesity agents and obesity therapeutic treatment
targets. Obes Res 2004; 12: 1197-1211.
39. Korner J, Aronne LJ. Pharmacological approaches to
weight reduction: therapeutic targets. J Clin Endocrinol
Metabol 2004; 89: 2616-1621.
40. Shi Y, Burn P. Lipid metabolic enzymes: emerging drug targets
for the treatment of obesity. Nature Rev 2004; 3: 695-
710.
41. Gadde KM, Parker CB, Maner LG, Wagner HR, Logue EJ,
Drezner MK, et al. Bupropion for weight loss: an investigation
of efficacy and tolerability in overweight and obese
women. Obes Res 2001; 9: 544 –551.
42. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney
J, O’Neil PM. Bupropion SR enhances weight loss: a 48-
week double-blind, placebo-controlled trial. Obes Res
2002; 10: 633-641.
43. Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB,
Brewer ER, et al. Bupropion SR vs. placebo for weight loss in
obese patients with depressive symptoms. Obes Res 2002;
10:1049-1056.
44. Astrup A, Toubro S. Topiramate: a new potential pharmacological
treatment for obesity. Obes Res 2004; 12: 167S-
173S.
45. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M,
Perry BH, for the U.S. Topiramate Research Group. A 6-
month randomized, placebo-controlled, dose-ranging trial
of topiramate for weight loss in obesity. Obes Res. 2003; 11:
722-733.
46. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M
for the OBES-002 Study Group. A randomized double-blind
placebo-controlled study of the long-term efficacy and
safety of topiramate in the treatment of obese subjects. Int
J Obes 2004; 28: 1399–1410.
47. McElroy SL, Arnold LM, Shapira NA, Keck PE, Jr., Rosenthal
NR, Karim MR, et al. Topiramate in the treatment of binge
eating disorder associated with obesity: a randomized,
placebo-controlled trial. Am J Psychiatry 2003; 160:255–226.
48. Gadde KM, Franciscy DM, Wagner HR, Krishnan KR. Zonisamide
for weight loss in obese adults. A randomized controlled
trial. JAMA 2003; 289: 1820-1825.
49. Duff E, Baile CA. Ciliary neurotrophic factor: a role in obesity?
Nutr Rev 2003; 61: 423-426.
50. Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, Mellwain
HH, Heymsfield SB. Recombinant variant of ciliary neutrophic
factor for weight loss in obese adults. A randomized,
dose-ranging study. JAMA 2003; 289: 1826-1832.
51. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide,
a long-acting glucagon-like peptide 1 derivative, on
glycemic control, body composition, and 24-h energy expenditure
in patients with type 2 diabetes. Diabetes Care
2004; 27:2915-2921.
52. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2
diabetes mellitus. Nat Rev Endocrinol 2009; 5: 262-9.
53. Reda TK, Geliebter A, Pi-Sunyer FX. Amylin, food intake,
and obesity. Obes Res 2002; 10: 1087-1091.
54. Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L,
Kolterman OG, et al. Effect of pramlintide on weight in
overweight and obese insulin-treated type 2 diabetes patients.
Obes Res 2004; Obes Res 2004 12:661-668.
55. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP,
Larsen TM. Effect of tesofensine on bodyweight loss, body
composition, and quality of life in obese patients: a randomised,
double-blind, placebo-controlled trial. Lancet
2008; 378: 1906-13.
56. Smith SR,Prosser W, Donahue D, Morgan ME, Anderson
CM, Shanahan WR. Lorcaserin (APD356), an orally-active
selective 5-HT2C agonist reduces body weight in obese
men and women. Obesity 2008; 17:494-503.
57. Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962),
a novel lipase inhibitor: a 12-week randomized, placebocontrolled
study of weight reduction in obese patients. Int
J Obes (Lond) 2007;31:494–9.
58. Kopelman P, de H Groot G, Rissanen A, et al. Weight loss,
HbA(1c) reduction, and tolerability of cetilistat in a randomized,
placebo-controlled phase 2 trial in obese diabetics:
Comparison with orlistat (Xenical). Obesity 2009
[Epub ahead of print] DOI: 10.1038/oby.2009.155.
59. Bray GA. Medications for weight reduction. Endocrinol
Metab Clin N Am 2008; 37: 923–42.
60. Chakrabarti R. Pharmacotherapy of obesity: emerging
drugs and targets. Expert Opin Ther Targets 2009; 13: 295-
302.